Standpoint Research Downgrades Teva Pharma (TEVA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Teva Pharma (TEVA) / Mylan (MYL) Combo Unlikely, Says Wells Fargo
October 3, 2014 1:24 PM EDTWells Fargo analyst Michael Faerm commented on speculation Teva Pharma (NYSE: TEVA) is interested in acquiring Mylan (NASDAQ: MYL). In his view, a potential deal has positives and negatives, and while it may be financially attractive he thinks it... More
